EP1081148B1 - Enantiomerisch reine Beta-D-Dioxolan-Nukleoside - Google Patents

Enantiomerisch reine Beta-D-Dioxolan-Nukleoside Download PDF

Info

Publication number
EP1081148B1
EP1081148B1 EP00203932A EP00203932A EP1081148B1 EP 1081148 B1 EP1081148 B1 EP 1081148B1 EP 00203932 A EP00203932 A EP 00203932A EP 00203932 A EP00203932 A EP 00203932A EP 1081148 B1 EP1081148 B1 EP 1081148B1
Authority
EP
European Patent Office
Prior art keywords
dioxolane
compound
nucleosides
pharmaceutically acceptable
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00203932A
Other languages
English (en)
French (fr)
Other versions
EP1081148A2 (de
EP1081148A3 (de
Inventor
Chung K. Chu
Raymond F. Schinazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia
Emory University
University of Georgia Research Foundation Inc UGARF
Original Assignee
University of Georgia
Emory University
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25467279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1081148(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Georgia, Emory University, University of Georgia Research Foundation Inc UGARF filed Critical University of Georgia
Publication of EP1081148A2 publication Critical patent/EP1081148A2/de
Publication of EP1081148A3 publication Critical patent/EP1081148A3/de
Application granted granted Critical
Publication of EP1081148B1 publication Critical patent/EP1081148B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • This invention is in the area of organic compounds with antiviral activity, and in particular provides pharmaceutical compositions comprising an effective amount of one or more enantiomerically pure ⁇ -D-dioxolane nucleosides.
  • a number of 2', 3'-dideoxynucleosides have been found to be potent antiviral agents against human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS).
  • HIV human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • AZT 3'-azido-2'-deoxythymidine, Mitsuya, H-; Broder, S. Proc. Natl. Acad. Sci. U.S.A., 198G 83, 1911
  • these synthetic nucleosides may be incorporated into a growing strand of viral DNA, causing chain termination due to the Absence of the 3'-hydroxyl group.
  • nucleoside derivatives play an important role in their biological activity.
  • the C1' position of the ribose in the nucleoside (the carbon bound to the nitrogen of the heterocyclic base) is a chiral center because the carbon is attached to four different moieties.
  • there is an optically active center at C4' of the nucleoside (the ring carbon bound to the hydroxymethyl group that is phosphorylated in nuoleotides).
  • the base attached to the C1' and the hydroxymethyl group attached to the C4' atom are in the ⁇ -configuration (above the plane of the sugar).
  • the corresponding non-naturally occurring ⁇ -isomers (in which the moieties are below the plane of the sugar) are rarely biologically active, and are typically toxic.
  • the product was synthesized in five steps from benzyloxyaldehyde dimethylacetal and ( ⁇ )-methyl glycerate to produce a 79% yield of the 1:1 diastereomeric mixture.
  • the X-ray crystallographic analysis of the product revealed that the dioxolane ring adopts the 3 T, conformation commonly observed in ribonucleosides, with the 03' atom in the endo position.
  • Norbeck reported that the racemic mixture of dioxolane-T exhibits an anti-HIV activity of 20 ⁇ M in ATH8 cells, and attributed the low efficacy against the virus to an effect of the endo conformation of the O3' atom.
  • Belleau et al., in the Fifth International Conf. on AIDS, Montreal, Canada June 4-9, 1990, paper, No. T.C.O.1., reported a method of synthesis of cytidine nucleosides that contain oxygen or sulfur in the 3'-position.
  • the dioxolane ring was prepared by the condensation of RCO 2 CH 2 CHO with glycerin.
  • the Belleau synthesis results in a racemic mixture of diastereoisomers about the C4' carbon of the nucleoside.
  • Belleau reported that the sulfur analog, referred to as NGBP-21 or ( ⁇ ) BCH-189 (see Figure 1 ), has anti-HIV activity.
  • WO92/10497 discloses an asymmetric synthesis for the production of ⁇ -D-dioxolane ncleosides, including (-)-(2R,4R)-9-[(2-hydroxylmethyl)-1,3-dioxolan-4-yl]guanine, which comprises preparing the dioxolane ring from 1,6-anhydromannose.
  • Disclosed herein is a method of synthesis of enantiomerically pure dioxolane nucleosides.
  • a pharmaceutical composition comprising an effective amount of an enantiomerically pure ⁇ -D-dioxolanyl purine nucleoside of the structure: wherein R is Cl, NH 2 , or H and X is selected from she group consisting of H, acyl, monophosphate, diphosphate and triphosphate or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.
  • R is Cl, NH 2 , or H
  • X is selected from she group consisting of H, acyl, monophosphate, diphosphate and triphosphate or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.
  • the compound wherein X is H and R is chloro is specifically referred to as (-)-(2R,4R)-2-amino-6-chloro-9-[(2-hydroxymethyl)-1,3-dioxlan-4-yl]purine.
  • the compound wherein X is H and R is amino is (-)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-l13-dioxolan-4-yl]adenine.
  • the compound wherein X is H and R is hydrogen is (-)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]purine.
  • the acyl group is a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic C 1 -C 20 alkyl alkoxyalkyl including methoxymethyl; aralkyl including benzyl; aryloxyalkyl such as phenoxymethyl; aryl including phenyl optionally substituted with halogen, C 1 to C 4 alkyl or C 1 to C 4 alkoxy; a dicarboxylic acid such as succinic acid; sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl; and the mono, di and triphosphate esters.
  • the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic C 1 -C 20 alkyl alkoxyalkyl including methoxymethyl; aralkyl including benzyl; aryloxyalkyl such
  • alkyl specifically includes but is not limited to methyl, ethyl propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, t-butyl, isopentyl, amyl, t-pentyl, cyclopentyl, and cyclohexyl.
  • acyl specifically includes but is not limited to acetyl, propionyl, butyryl, pentanoyl, 3-methylbutyryl, hydrogen succinate, 3-chlorobenzoate, benzoyl, acetyl, pivaloyl, mesylate propionyl, valeryl, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, and oleic. Modifications of the active compound, specifically at the N 6 and 5'-O positions, can affect the bioavailability and rate of metabolism of the active species, thus providing control over the delivery of the active species.
  • the enantiomerically pure ⁇ -D-dioxolanyl purine nucleoside can be converted into a pharmaceutically acceptable ester by reaction with an appropriate esterifying agent, for example, an acid halide or anhydride.
  • the nucleoside or its pharmaceutically acceptable derivative can be converted into a pharmaceutically acceptable salt thereof in a conventional manner, for example, by treatment with an appropriate base.
  • the ester or salt can be converted into the parent nucleoside, for example, by hydrolysis.
  • ⁇ -D-dioxolane nucleosides or their pharmaceutically acceptable derivatives or salts or pharmaceutically acceptable formulations containing these compounds are useful in the treatment of HIV infections and other related conditions such as AIDS-related complex (ARC), persistent generalized lymphadenopathy (PGL), AIDS-related neurological conditions, anti-IIIV antibody positive and HIV-positive conditions, Kaposi's sarcoma, thrombocytopenia purpurea and opportunistic infections.
  • these compounds or formulations can be used prophylactically to retard the progression of clinical illness in individuals who are anti-IIIV antibody or HIV-antigen positive or who have been exposed to HIV.
  • Disclosed herein is an asymmetrie process for the preparation of enantiomerically pure ⁇ -D-dioxolane-nucleosides,
  • the process involves the initial preparation of (2R,4R)- and (2R,4S)-4-acetoxy-2-(protected-oxymethyl)-dioxolane from 1,6-anhydromannose, a sugar that contains all of the necessary stereochemistry for the enantiomerically pure final product, including the correct disastercomerie configuration about the 1 position of the sugar (that becomes the 4'-position in the later formed nucleoside).
  • the (2R,4R)- and (2R,4S)-4-acetoxy-2-(protected-oxymethyl)-dioxolane is condensed with a desired heterocyclic base in the presence of SnCl 4, other Lewis acid, or trimethylsilyl triflate in an organic solvent such as dichloroethane, acetonitrile, or methylene chloride, to provide the stereochemically pure dioxolane-nucleoside.
  • Any desired enantiomerically pure ⁇ -D-dioxolane purine or pyrimidine nucleoside can be prepared according to the process disclosed herein.
  • the product can be used as a research tool to study the inhibition of HIV in vitro or can be administered in a pharmaceutical composition to inhibit the growth of HIV in vivo.
  • enantiomerically pure refers to a nucleoside composition that includes at least 97% of a single enantiomer of that nucleoside.
  • 1,6-anhydromannose (compound 1, Figure 2 ).
  • This sugar contains all of the necessary stereochemistry for the enantiomerically pure final product (see for example, compound 11, Figure 2 ), including the correct diastereomeric configuration about the 1 position of the sugar (that becomes the 4'-position in the later formed nucleoside).
  • 1,6-Anhydromannose can be prepared according to procedures described in Knauf, A.E.; Hann, R.M.; Hudson, C.S. J. Am. Chem.
  • the 1,6-anhydromannose is converted to its isopropylidene derivative with dimethoxypropane and p-toluenesulfonic acid, which, without isolation, is benzoylated in the 4-position to compound 2 (see Figure 2 ).
  • An acyl group can also be used to protect the 4-position.
  • the isopropylidene group of compound 2 is then removed by a catalytic amount of an acid such as sulfuric acid, hydrochloric acid, formic acid, trifluoroacetic acid, sulfamic acid, in 60% aqueous dioxane or other suitable organic solvent at a temperature range of approximately 0 to 50°C to give (-)-1,6-anhydro-4-0-benzoyl- ⁇ -D-mannopyranose in high yield as a white solid.
  • an acid such as sulfuric acid, hydrochloric acid, formic acid, trifluoroacetic acid, sulfamic acid
  • the glycol of (-)-1,6-anhydro-4-0-benzoyl- ⁇ -D-mannopyranose is oxidatively cleaved by treatment with NaIO 4 in H 2 O/EtOH (1:1) for one hour at approximately room temperature to produce to the corresponding dialdehyde.
  • Lead tetraacetate can also be used as the oxidizing reagent for this reaction.
  • dialdehyde is immediately reduced in situ with any suitable reducing agent, including NaBH 4 , diisobutylaluminum hydride (DIBAL-H), lithium borohydride (LiBH 4 ), or sodium bis(2-methoxyethoxy)-aluminum hydride (Red-Al), at approximately room temperature or below.
  • any suitable reducing agent including NaBH 4 , diisobutylaluminum hydride (DIBAL-H), lithium borohydride (LiBH 4 ), or sodium bis(2-methoxyethoxy)-aluminum hydride (Red-Al)
  • compound 4 isomerizes by benzoyl migration from a secondary to a primary position to produce (-)-(2R,4R)-4-(2-benzoxy-1-hydroxyethyl) -2-(hydroxymethyl)-dioxolane (compound 5, Figure 2 ).
  • the 2-position of the dioxolane is then protected with a suitable oxygen protecting group, for example, a trisubstituted silyl group such as trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, trityl, alkyl group, acyl groups such as acetyl, propionyl, benzoyl, p-NO 2 benzoyl, or toluyl, methylsulfonyl, or p-toluylsulfonyl.
  • a preferred protecting group is t-butyldiphenylsilyl.
  • the benzoyl group is removed from the 2-hydroxyethyl-position with a strong base such as sodium methoxide or ammonia in methanol at approximately 0 to 50°C to produce (-)-(2R,4R)-2-(protected-O-methyl)-4-(1,2-dihydroxyethyl)-dioxolane (compound 6, Figure 2 ) in high yield.
  • a strong base such as sodium methoxide or ammonia in methanol
  • the 1,2-dihydroxyethyl group in the 4-position of the dioxolane is converted to a carboxylic acid with an oxidizing agent such as NaIO 4 /RuO 2 or lead tetraacetate, at approximately 0 to 50°C to produce (+)-(2R,4R)-2-(protected-oxymethyl)-4-carboxyldioxolane (see compound 7, Figure 2 ).
  • an oxidizing agent such as NaIO 4 /RuO 2 or lead tetraacetate
  • a modified Hunsdiecker reaction ( Dhavale, D.; et al., Tetrahedron Lett., 1988, 29, 6163 ) is then carried out in ethyl acetate with Pb(OAc) 4 to convert (+)-(2R,4R)-2-(protected-oxymethyl)-4-carboxyldioxolane to the corresponding key intermediates (2R,4R)- and (2R, 4S)-4-acetoxy-2-(protected-oxymethyl) dioxolane (see compound 8 , Figure 2 ) in good yield.
  • the enantiomerically pure dioxolane prepared as described in Section A. is condensed with a protected base in the presence of trimethylsilyl triflate (trimethylsilyl trifluoromethanesulfonate) or a Lewis acid in a dry organic solvent.
  • Purine bases include but are not limited to adenine, hypoxanthine, 2,6-diaminopurine, 6-amino-2-chloropurine, 2-aminopurine, N 6 -alkylpurines, N 6 -benzylpurine, N 6 -halopurine, and guanine.
  • Pyrimidine bases include but are not limited to thymine, cytosine, 6-azapyrimidine, 2-mercaptopyrimidine, and uracil.
  • Protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, tritylmethyl, alkyl groups, acyl groups such as acetyl and propionyl, methylsulfonyl, and p-toluylsulfonyl.
  • Friedel-Crafts catalysts that can be used in the condensation reaction include SnCl 4 , ZnCl 4 , TiCl 4 , AlCl 3 , FeCl 3 , BF 3 -diethylether, and BCl 3 . These catalysts require anhydrous conditions because the presence of water reduces their activity. The catalysts are also inactivated in the presence of organic solvents with active hydrogens, such as alcohols and organic acids.
  • the catalysts are typically used in solvents such as carbon disulfide, methylene chloride, nitromethane, 1,2-dichloroethane, nitrobenzene, tetrachloroethane, chlorobenzene, benzene, toluene, dimethylformamide, tetrahydrofuran, dioxane, or acetonitrile.
  • solvents such as carbon disulfide, methylene chloride, nitromethane, 1,2-dichloroethane, nitrobenzene, tetrachloroethane, chlorobenzene, benzene, toluene, dimethylformamide, tetrahydrofuran, dioxane, or acetonitrile.
  • Anhydrous aluminum chloride is not soluble in carbon disulfide. Niedballa, et al., J. Org. Chem. 39, 25 (1974 ).
  • the preferred catalyst is SnCl 4
  • Trimethylsilyl triflate can be used under the same conditions described above for the Friedel-Crafts catalysts. The reaction proceeds at a temperature range of from -10°C to 200°C. The choice of catalyst for condensation will affect the final product ratio of ⁇ to B nucleoside product.
  • the initially formed N 7 -isomer was again converted to the N 9 -isomer during stirring overnight at room temperature.
  • the analytical sample was obtained from the separation of ⁇ , ⁇ -mixture to the individual isomers 13 and 14 by a preparative TLC using CH 2 Cl 2 -acetone (19:1) as the developing solvents.
  • the mixture of 13 and 14 was treated with NH 3 in DME (Robins, M.J.; Vznanski, B.
  • Nucleic acid related compounds. 34 Non-aqueous Diazotization with tert-Butyl nitrite. Introduction of Fluorine, Chlorine, and Bromine at C-2 of Purine Nucleosides. Can. J. Chem. 1981, 2608) to give a mixture of 21-24, which was separated to the individual isomers 15 (24%), 16 (18.6%), 17 (25.8%) and 18 (16%).
  • the guanine 19 and 2,6-diamino 20 derivatives were prepared by the treatment of 15 with 2-mercaptoethanol/NaOMe and ammonia in ethanol, respectively.
  • the free nucleosides 21-26 were obtained upon treatment of the corresponding 5'-silylated nucleosides with n-Bu 4 NF in good yields.
  • the ⁇ -isomers 23 and 24 were also prepared by the similar procedure as the ⁇ -isomers.
  • the 5'-O-position of the nucleoside is deprotected.
  • Desilylation can be carried out with a variety of reagents, including acetic acid, trifluoroacetic acid, hydrogen fluoride, n-tetrabutylammonium fluoride, potassium fluoride and pyridinium HCl.
  • acetic acid is preferred for commercial scale use because it is inexpensive.
  • Other reagents for desilylation are known to those skilled in the art.
  • Deacylation is accomplished in acid or base. 5-O-Ethers can be cleaved with BCl 3 or trimethylsilyl iodide.
  • Example 1 sets out in detail a method for the preparation of (2R,4R)- and (2R,4S)-4-acetoxy-2-(t-butyldiphenylsilyoxymethyl)dioxolane (compound 8, Figure 2 ).
  • Example 2 sets out the preparation of (-)-1-[(2 ⁇ ,4 ⁇ )-2-(hydroxymethyl)-4-dioxolanyl]thymine, referred to as (-)- ⁇ -D-dioxolane-T.
  • the enumeration of compounds in Example 2 refer to structures set out in Figure 2 .
  • Example 3 provides detailed examples for the preparation of a number of enantiomerically pure ⁇ -D-dioxolanyl nucleosides, including (-) - (2R,4R) -2-amino-6-chloro-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]purine, (-)-(2R,4R)-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]guanine, and (-)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]adenine.
  • 1,6-anhydro- ⁇ -D-mannopyranose (compound 1) was mixed with acetone (800 ml) and methanol (300 ml) and stirred for approximately thirty minutes until only a free-flowing solid remained. Dimethoxypropane (300 ml), and p-toluenesulfonic acid (5 g) were then added, and the mixture stirred for 2 hours.
  • reaction mixture was then made basic with triethylamine (pH 8), and filtered to remove the white solid material.
  • the solvents were evaporated, and the residue taken up in ethyl acetate and then crystallized to obtain 4 grams of the 2,3-isopropylidenated product as clear needles.
  • Anal. (C 25 H 28 FN 5 O 3 Si) C, H, F, N, 17 (R f 0.43, 1.60 g, 25.76%): a white crystalline solid.
  • Anal. (C 25 H 28 FN 5 O 3 Si) C, H, F, N. 18 (R f 0.12, 0.96 g, 16%), a microcrystalline solid.
  • (-)-(2R,4R)-2-Amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]purine can be prepared by reduction of compound 21 using a variety of reducing agents, including palladium on carbon and hydrogen gas or tributyltin hydride and azabisisobutyronitrile.
  • ⁇ -D-Dioxolane-nucleosides can be used as research tools to inhibit the growth of HIV in vitro , or can be administered to humans pharmaceutically to inhibit the growth of HIV in vivo.
  • ⁇ -D-dioxolane-nucleosides to inhibit HIV can be measured by various experimental techniques.
  • the technique used herein, and described in detail below measures the inhibition of viral replication in phytohemagglutinin (PHA) stimulated human peripheral blood mononuclear (PBM) cells infected with HIV-1 (strain LAV).
  • PHA phytohemagglutinin
  • PBM human peripheral blood mononuclear
  • strain LAV HIV-1
  • the amount of virus produced is determined by measuring the virus-coded reverse transcriptase enzyme.
  • the amount of enzyme produced is compared to an HIV control. The method is described in detail below.
  • the percent inhibition of virus as determined from measurements of reverse transcriptase, is plotted versus the micromolar concentration of compound.
  • the EC 50 is the concentration of compound at which there is a 50% inhibition of viral growth.
  • the toxicities of compounds 21 , 25 , and 26 Were evaluated in uninfected human PDM cells, CEM cells (T-lymphoblactoid cell line obtained from ATCC, Rockville, MD) and Vero (African Green Monkey kidney) cells. The three compounds were not toxic in any of the cell lines at a concentration of 100 ⁇ M.
  • Humans suffering from HIV infection can be treated by administering to the patient an effective amount of (-)-(2R,4R)-2-amino-6-chloro-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]purine;
  • active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form
  • the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient as therapeutically effective amount without causing serious toxic effects in the patient treated.
  • a preferred dose of the active compound for all of the above-mentioned conditions will be in the range from about 1 to 60 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day.
  • the effective dosage range of the pharmaceutically acceptable derivatives can be calculated based on the weight of the parent nucleoside to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other mean a known to those skilled in the art.
  • the compound is conveniently administered in unit any suitable dosage form, including but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form.
  • An oral dosage of 50-1000 mg is usually convenient.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 ⁇ M, preferably about 1.0 to 10 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
  • the concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
  • the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the active compound or pharmaceutically acceptable salt or derivative thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the active compound, or pharmaceutically acceptable derivative or salt thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, or other antivirals, including other nucleoside anti-HIV compounds.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • preferred carriers are physiological saline or phosphate buffered saline (PBS).
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811 (which is incorporated herein by reference in its entirety).
  • liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container.
  • aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives are then introduced into the container.
  • the container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • Mono, di, and triphosphate derivative of ⁇ -D-dioxolane-nucleosides can be prepared as described below.
  • the monophosphate can be prepared according to the procedure of Imai et al., J. Org. Chem., 34(6), 1547-1550 (June 1969 ). For example, about 100 mg of B-D-dioxolane-nucleoside and about 280 ⁇ l of phosphoryl chloride are reacted with stirring in about 8 ml of dry ethyl acetate at about 0°C for about four hours. The reaction is quenched with ice. The aqueous phase is purified on an activated charcoal column, eluting with 5% ammonium hydroxide in a 1:1 mixture of ethanol and water. Evaporation of the eluant gives ammonium-( ⁇ -D-dioxolane-nucleoside) -5'-monophosphate.
  • the diphosphate can be prepared according to the procedure of Davisson et al., J. Org. Chem., 52(9), 1794-1801 (1987 ).
  • ⁇ -D-Dioxolane-nucleosides can be prepared from the corresponding tosylate, that can be prepared, for example, by reacting the nucleoside with tosyl chloride in pyridine at room temperature for about 24 hours, working up the product in the usual manner (e.g., by washing, drying, and crystallizing it).
  • the triphosphate can be prepared according to the procedure of Hoard et al., J. Am. Chem. Soc., 87(8), 1785-1788 (1965 ).
  • ⁇ -D-dioxolane-nucleoside is activated (by making a imidazolide, according to methods known to those skilled in the art) and treating with tributyl ammonium pyrophosphate in DMF.
  • the reaction gives primarily the triphosphate of the nucleoside, with some unreacted monophosphate and some diphosphate. Purification by anion exchange chromatography of a DEAE column is followed by isolation of the triphosphate, e.g., as the tetrasodium salt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (8)

  1. Pharmazeutische Zusammensetzung umfassend eine wirksame Menge eines enantiomer reinen β-D-Dioxolanylnucleosids der Struktur:
    Figure imgb0004
     wobei R H, NH2 oder Cl ist und X aus der Gruppe ausgewählt ist bestehend aus Wasserstoff, Acyl, Monophosphat, Diphosphat und Triphosphat oder ihr pharmazeutisches Salz, zusammen mit einem pharmazeutisch akzeptablen Träger oder einem pharmazeutisch akzeptablen Verdünnungsmittel;
    wobei die Verbindung zu mindestens 97 % von dem entsprechenden β-L-Enantiomer frei ist und
    wobei der pharmazeutisch akzeptable Träger oder das pharmazeutisch akzeptable Verdünnungsmittel für die orale Verabreichung geeignet ist.
  2. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei die Zusammensetzung in Form einer Dosiseinheit vorliegt.
  3. Pharmazeutische Zusammensetzung nach Anspruch 2, wobei die Dosiseinheit 7 bis 3000 mg der Verbindung oder ihres pharmazeutisch akzeptablen Salzes enthält.
  4. Pharmazeutische Zusammensetzung nach Anspruch 2, wobei die Dosiseinheit 70 bis 1400 mg der Verbindung oder ihres pharmazeutisch akzeptablen Salzes enthält.
  5. Pharmazeutische Zusammensetzung nach Anspruch 2, wobei die Dosiseinheit 50 bis 1000 mg der Verbindung oder ihres pharmazeutisch akzeptablen Salzes enthält.
  6. Pharmazeutische Zusammensetzung nach Anspruch 2, wobei die Dosiseinheit eine Tablette oder eine Kapsel ist.
  7. Pharmazeutische Zusammensetzung nach Anspruch 6, wobei die Dosiseinheit eine Tablette ist.
  8. Pharmazeutische Zusammensetzung nach Anspruch 6, wobei die Dosiseinheit eine Kapsel ist.
EP00203932A 1992-08-25 1993-08-25 Enantiomerisch reine Beta-D-Dioxolan-Nukleoside Expired - Lifetime EP1081148B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US935515 1992-08-25
US07/935,515 US5925643A (en) 1990-12-05 1992-08-25 Enantiomerically pure β-D-dioxolane-nucleosides
EP93920366A EP0656778B1 (de) 1992-08-25 1993-08-25 Enantiomerisch reine beta-d-dioxolan-nukleoside

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP93920366A Division EP0656778B1 (de) 1992-08-25 1993-08-25 Enantiomerisch reine beta-d-dioxolan-nukleoside
EP93920366.7 Division 1994-03-03

Publications (3)

Publication Number Publication Date
EP1081148A2 EP1081148A2 (de) 2001-03-07
EP1081148A3 EP1081148A3 (de) 2003-03-05
EP1081148B1 true EP1081148B1 (de) 2011-02-16

Family

ID=25467279

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00203932A Expired - Lifetime EP1081148B1 (de) 1992-08-25 1993-08-25 Enantiomerisch reine Beta-D-Dioxolan-Nukleoside
EP93920366A Expired - Lifetime EP0656778B1 (de) 1992-08-25 1993-08-25 Enantiomerisch reine beta-d-dioxolan-nukleoside

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP93920366A Expired - Lifetime EP0656778B1 (de) 1992-08-25 1993-08-25 Enantiomerisch reine beta-d-dioxolan-nukleoside

Country Status (12)

Country Link
US (2) US5925643A (de)
EP (2) EP1081148B1 (de)
JP (3) JP3519736B2 (de)
AT (2) ATE498624T1 (de)
AU (1) AU670637C (de)
CA (1) CA2143107C (de)
DE (2) DE69330274T2 (de)
DK (1) DK0656778T3 (de)
ES (1) ES2157929T3 (de)
GR (1) GR3036393T3 (de)
PT (1) PT656778E (de)
WO (1) WO1994004154A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
CN1196701C (zh) 1997-03-19 2005-04-13 埃莫里大学 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
DE19739827B4 (de) * 1997-09-11 2007-05-10 Robert Bosch Gmbh Verfahren und Vorrichtung zur Steuerung einer Betriebsgröße eines Kraftfahrzeugs
CN1666742A (zh) 1998-11-02 2005-09-14 三角药物公司 对乙型肝炎病毒的联合治疗
OA11741A (en) 1998-12-23 2005-05-13 Iaf Biochem Int Antiviral nucleoside analogues.
US6511983B1 (en) 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
WO2002031176A1 (fr) * 2000-10-12 2002-04-18 Mitsui Chemicals, Inc. Procédé permettant la production de nucléosides
KR101015510B1 (ko) 2001-03-01 2011-02-16 길리애드 사이언시즈, 인코포레이티드 시스-ｆｔｃ의 다형 및 기타 결정형
ES2360096T3 (es) * 2002-08-06 2011-05-31 Pharmasset, Inc. Procedimientos de preparación de nucleosidos de 1,3-dioxolano.
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
US7785839B2 (en) 2004-02-03 2010-08-31 Emory University Methods to manufacture 1,3-dioxolane nucleosides
US7446234B2 (en) * 2005-09-27 2008-11-04 Council Of Scientific And Industrial Research Bisphenol compound and process for preparation thereof
EP1940781A1 (de) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenylacetamid-nnrt-inhibitoren
MX2009001198A (es) 2006-08-16 2009-02-11 Hoffmann La Roche Inhibidores no nucleosidicos de la transcriptasa inversa.
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
WO2008145562A1 (en) 2007-05-30 2008-12-04 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
KR101610607B1 (ko) 2007-12-21 2016-04-07 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
DK2435825T3 (en) 2009-05-27 2015-10-19 Biotempus Ltd Modes for medical care
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
HUE026235T2 (en) 2010-03-31 2016-06-28 Gilead Pharmasset Llc Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5011774A (en) * 1987-07-17 1991-04-30 Bristol-Myers Squibb Co. Dideoxyinosine by enzymatic deamination of dideoxyadenosine
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5122517A (en) * 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
EP0375329B1 (de) * 1988-12-19 1995-05-31 The Wellcome Foundation Limited Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
CA2095533A1 (en) 1990-12-14 1992-06-15 Theodore D. Held, Iii Substantially phosphate free mildly acidic cleaner for plastics
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
KR100270806B1 (ko) * 1991-03-06 2000-11-01 템블 존 엘 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
JP2004149543A (ja) 2004-05-27
EP1081148A2 (de) 2001-03-07
EP0656778B1 (de) 2001-05-30
DE69330274D1 (de) 2001-07-05
DK0656778T3 (da) 2001-07-30
EP0656778A4 (de) 1995-08-02
JP4503206B2 (ja) 2010-07-14
AU670637B2 (en) 1996-07-25
ATE498624T1 (de) 2011-03-15
ES2157929T3 (es) 2001-09-01
AU670637C (en) 2002-07-25
PT656778E (pt) 2001-09-28
DE69334348D1 (de) 2011-03-31
CA2143107A1 (en) 1994-03-03
US5767122A (en) 1998-06-16
CA2143107C (en) 2004-11-23
US5925643A (en) 1999-07-20
AU5093393A (en) 1994-03-15
JP3519736B2 (ja) 2004-04-19
GR3036393T3 (en) 2001-11-30
EP0656778A1 (de) 1995-06-14
WO1994004154A1 (en) 1994-03-03
JPH08501086A (ja) 1996-02-06
ATE201599T1 (de) 2001-06-15
EP1081148A3 (de) 2003-03-05
DE69330274T2 (de) 2001-11-15
JP2002114787A (ja) 2002-04-16

Similar Documents

Publication Publication Date Title
EP1081148B1 (de) Enantiomerisch reine Beta-D-Dioxolan-Nukleoside
EP1164133B1 (de) Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside
WO1994004154A9 (en) ENANTIOMERICALLY PURE β-D-DIOXOLANE-NUCLEOSIDES
RU2126405C1 (ru) (-)-4-амино-5-фтор-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1h)-пиримидин- 2-он, смесь его энантиомеров, способы их получения, способ лечения
US5684010A (en) Enantiomerically pure β-D-dioxolane nucleosides with selective anti-hepatitis B virus activity
AU2003200421B2 (en) Enantiomerically pure beta-D-dioxolane-nucleosides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 656778

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07F 9/6561 B

Ipc: 7C 07D 473/00 A

Ipc: 7C 07D 405/04 B

Ipc: 7A 61K 31/52 B

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20030811

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20061205

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 0656778

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69334348

Country of ref document: DE

Date of ref document: 20110331

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 69334348

Country of ref document: DE

Effective date: 20110331

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110616

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110527

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110216

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110517

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110216

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110216

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110216

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20111117

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69334348

Country of ref document: DE

Effective date: 20111117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120430

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110216

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69334348

Country of ref document: DE

Effective date: 20120301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120301